A multiplex targeted Mass spectrometry approach for the quantification of synuclein proteoforms in human biological fluids

Innovative multiplex and targeted mass spectrometry method development for the quantification of the alpha, beta and gamma synuclein in biological samples as CSF and plasma in the context of neurodegenerative diseases. In the synucleopathy field, one of the main goals remains to discover biomarkers allowing to discriminate between Parkinson’s disease, Lewy Body dementia or Multi System Atrophy. For this purpose, alpha synuclein has been intensively studied due to its major presence in aggregates such as Lewy bodies, hallmark of these neurodegenerative diseases [Vinnakota et al, 2018; McLean et al, 2012]. Alpha synuclein and its proteoforms are present at different levels in brain and CSF indicating that they might be relevant biomarkers. [Schmid et al, 2013; Otto et al, 2019; Zetterberg et al, 2019]. In this context, our objective is to develop a mass spectrometry multiplex method to quantify proteoforms of the synucleins family (alpha, beta and gamma) in human biological fluid (CSF, plasma).

Content Type:
Document Number:
ASMS 2020 - TP 535
Product Type:
Liquid Chromatography Mass Spectrometry (LC-MS)
Clinical Research & Medical Devices, LCMS-9030 Q-TOF Mass Spectrometer, Nexera Mikros Microflow Liquid Chromatography Mass Spectrometer
File Name:
File Size:

View Article Question about this literature?

Top of This Page